Eisai Pipeline - Products - Performance - Potential

Publication Date	June 2008
Publisher	Espicom
Product Type	Report
Pages	114
ISBN Number	not applicable
Product Code	ESP00566

Price

£595.00
approximately: $869 | €652

PDF

Order above formats by FAX

Summary

Headquartered in Japan, Eisai operates in two main business areas: Pharmaceuticals, including ethical drugs, OTC products and diagnostics; and Others, which comprises pharmaceutical production systems and equipment. Eisai has clinical research bases in North America, Europe, Asia and Japan, and employs over 10,600 people worldwide. Eisai sells prescription products within the following therapeutic areas: neurology; gastroenterology; metabolic; anti-inflammatory; diagnostics and oncology. It is now focusing its research and development efforts on neurology, gastroenterology and oncology/critical care.

Foreign subsidiaries and operations generated 57.4 per cent of Eisai's sales in fiscal 2008 (compared to 52.6 per cent in fiscal 2006), and the company continues to strive to create efficient global management. Much of Eisai's globalisation has been generated through the success of its two core products: Aricept, for the treatment of Alzheimer's disease, and Aciphex/Pariet, a therapy for gastric acid-related conditions. In order to maximise the value of these products abroad, Eisai recognised the need for strategic alliances with companies with greater experience in foreign markets. Therefore, Eisai has been marketing Aricept in various markets with the pharmaceutical giant Pfizer since November 1994, and Aciphex/Pariet has benefited from co-marketing with Janssen Pharmaceutica (a major subsidiary of Johnson & Johnson) in both European and US markets since January 1997. Such is Eisai's confidence in the recognition and standing of these products, and in its own US operations, the company assumed total control over the marketing of Aricept in the US in September 2005, and of Aciphex/Pariet, earlier in January 2004. Eisai is now targeting the emerging markets of China and India and, in October 2004, established the first Japanese pharmaceutical subsidiary in India, followed in March 2007, by the establishment of an active pharmaceutical ingredient R&D and manufacturing subsidiary, Eisai Pharmatechnology Manufacturing Pvt Ltd in Vishakhapatnam, which will commence operations in fiscal 2010. Eisai will be committing resources to these markets on a priority basis, thus laying the foundations for future business.

Both of the aforementioned products will be the key growth drivers for Eisai in the short-term, however, pending patent expirations (25th November 2010, for Aricept, and May 2013, for Aciphex/Pariet) are a serious concern for the company which will need to be addressed. Eisai has responded by targeting a new therapeutic area of interest, oncology and critical care. Eisai believes this field has significant levels of unmet needs and therefore, the potential to generate growth in the long-term. Eisai's confidence and dedication to this strategy has been demonstrated by its recent acquisitions of Morphotek and MGI Pharma, two biopharmaceutical companies with extensive history in the field of oncology. Eisai has also purchased rights to five oncology products from Ligand Pharmaceuticals.Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Content

Latest Results
Executive Summary
- Introduction
- Current Financial Position
  - Company Performance
  - Business Segment Performance
  - Geographic Segment Performance
- Company Strategy
  - Geographic Strategy
  - Production
  - Employees
  - R&d Strategy
  - Mergers, Acquisitions and Divestitures
  - Key Agreements
- Product Performance Forecasts
- Pipeline Analysis
- Discontinued R&d Projects
- Conclusions
Therapeutic Area Focus
R&d Pipeline
Neurology
- Marketed Products
- Aricept
- Inovelon
- Methycobal/Nabolin S
- Neurobloc
- Other Neurology Products
- R&d Projects
- E2012
- E2508
- E6201
- Eszopiclone
- Permapanel
- Ranirestat
- Growth Forecast
Gastroenterology
- Marketed Products
- Aciphex/Pariet
- R&d Projects
- Gasmotin/Gasmotine
- Growth Forecast
Metabolic
- Marketed Products
- R&d Projects
- Glufast
- Sa-001
- Sibutramine
- Growth Forecast
Diagnostics
- Marketed Products
- R&d Projects
- E7210
- Growth Forecast
Cardiovascular and Respiratory
- Marketed Products
- R&d Projects
- E5555
- Growth Forecast
Anti-Infectives
- Marketed Products
- R&d Projects
- Clevudine
- E1224
- Eritoran
- Growth Forecast
Oncology
- Marketed Products
- Ontak
- Panretin
- Targretin
- R&d Projects
- E6201
- E7080
- E7107
- E7820
- E7974
- Eribulin
- Indislam
- Morab-003
- Morab-009
- Growth Forecast
Other
- Marketed Products
- Actonel
- Talion
- R&d Projects
- Adalimumab
- E6007
- E6201
- Iguratimod
Appendix 1 - Financial Performance
- Full Year Results 2007
Appendix 2 - Key Corporate Events
Appendix 3 - Key Agreements
- Abbott
- Ajinomoto/Sanofi-Aventis
- Asahi Kasei Pharma Corporation
- Bioarctic Neuroscience Ab
- Bukwang Pharm
- Cmc Biopharmaceuticals
- Dainippon Sumitomo Pharma
- Dnavec Corporation
- Elan Corporation Plc
- Glaxosmithkline Plc
- Janssen Pharmaceutica
- Kissei Pharmaceuticals
- Ludwig Institute for Cancer Research
- Minophagen Pharmaceutical Co Ltd
- Multicell Technologies Inc
- National Cancer Institute
- Nitto Denko Corporation
- Novartis
- Pfizer
- Radius Health Inc
- Salix Pharmaceuticals Inc
- Sepracor Inc
- Solstice Neurosciences Inc
- Solvay
- Torreypines Therapeutics Inc
- Toyama Chemical Co Ltd
- Wyeth
- Others
Appendix 4 - Infrastructure
- Research and Development Facilities
- Manufacturing Facilities
Appendix 5 - Major Pharmaceutical
Subsidiaries/Joint Ventures
- Subsidiaries
- Joint-Venture Companies
Index of Tables
- Principal Operating Results
- Sales by Business Area
- Operating Income (Loss) by Business Area
- Capital Expenditure by Business Area
- Total Assets by Business Area
- Sales by Destination
- Sales by Origin
- Operating Income (Loss) by Geographical Area
- Total Assets by Geographical Area
- Employees by Geographical Location
- Recent Product Approvals
- Major Products, Therapeutic Areas and Sales
- Major Neurology Products, 2007
- Major Gastroenterology Products, 2007
- Major Metabolic Products, 2007
- Major Diagnostic Products, 2007
- Major Cardiovascular and Respiratory Products, 2007
- Major Domestic Subsidiaries
- Major North American Subsidiaries
- Major European Subsidiaries
- Major Asian Subsidiaries
Index of Charts
- Sales by Business Area
- Operating Income (Loss) by Business Area
- Capital Expenditure by Business Area
- Total Assets by Business Area, 2007
- Sales by Destination, 2007
- Sales by Origin
- Operating Income (Loss) by Geographical Area
- Total Assets by Geographical Area
- Employees by Geographic Segment, 2007
- Employees and Productivity
- Sales of Current Major Products (2002a-2012e)
- Sales of Major Products, 2007
- Aricept Sales (2002a-2012e)
- Inovelon Sales (2008e-2012e)
- Methycobal Sales (2002a-2012e)
- Neurobloc Sales (2008e-2012e)
- Perampanel Sales (2008e-2012e)
- Ranirestat Sales (2009e-2013e)
- Aciphex/Pariet Sales (2002a-2012e)
- Selbex Sales (2002a-2012e)
- Gasmotin Sales (2009e-2013e)
- Sibutramine Sales (2009e-2013e)
- Eritoran Sales (2011e-2015e)
- Adalimumab Sales (2008e-2012e)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&d Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity